2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1740

Fc-Derived Immunodominant Peptides Stimulate Natural Regulatory T Cells: A New Avenue to Overcome Defects in the Fc Antigen Processing and Restore Immune Regulation in Rheumatic Diseases
Abstract Number: 262

FDG PET/CT Visualization of Inflammation in Temporal and Maxillary Arteries in Treatment-Naive GCA Patients
Abstract Number: 1855

Feasibility and Preliminary Effects of a Novel Rehabilitation Strategy to Improve Hand and Arm Function in Systemic Sclerosis
Abstract Number: 2199

Feasibility of a Novel Approach to Studying Early Knee Osteoarthritis: An Offspring Study
Abstract Number: 394

Female Tumor Necrosis Factor Transgenic Mice Have More Severe Arthritis Than Males and Supporessed Levels of Bifidobacterium Pseudolongum in Their Gut Microbiome
Abstract Number: 1928

Fibroblast-like Synovial Cell Production of ED-a Fibronectin Contributes to Inflammation in Osteoarthritis
Abstract Number: 1973

Fibromyalgia in Real Life a National French Web-Based Survey in 4516 Patients
Abstract Number: 1991

Fibromyalgia in Russian Refugees: Translation and Validation of the Revised Symptom Impact Questionnaire
Abstract Number: 163

Fibromyalgia Patients Identify More Causes of Disease Flare Ups Than RA Patients
Abstract Number: 160

Fibromyalgia Screening Form in the Diagnosis of Concomitant Fibromyalgia
Abstract Number: 519

Filgotinib, a Selective Janus Kinase 1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects
Abstract Number: 4L

Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease
Abstract Number: 2832

Finding the Optimal Treatment Strategy for Disease Activity-Guided Dose Reduction of Adalimumab and Etanercept in Rheumatoid Arthritis: A Modelling Study
Abstract Number: 171

Finding Transcriptional Regulators Central to RA with Transcriptomics of IL17 Dose Response, Time Series, and siRNA Silencing in Stromal Cells
Abstract Number: 2826

Fine-Mapping Identifies Causal Variants for RA and T1D in DNASE1L3, Sirpg, MEG3, TNFAIP3 and CD28/CTLA4 Loc

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].